Tempest Therapeutics is a development-stage biotechnology company advancing small molecules that modulate anti-tumor immunity pathways. The company has a balanced and deep pipeline consisting of first-in-class and potential best-in-class small molecule therapeutics that modulate distinct immune response pathways relevant to mounting an effective anti-tumor response.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 03/29/18 | $70,000,000 | Series B |
Eight Road Ventures F-Prime Capital Partners  Foresite Capital Lilly Asia Ventures Quan Capital Versant Ventures | undisclosed |
